1.
Ther Umsch
; 80(8): 367-372, 2023 Oct.
Artículo
en Alemán
| MEDLINE
| ID: mdl-37971528
RESUMEN
INTRODUCTION: The use of immune checkpoint inhibitors has fundamentally changed the treatment landscape of solid tumors in recent years. Even in advanced stages or in tumors with historically poor prognosis, such as triple-negative breast cancer, progression-free survival, as well as overall survival of affected individuals, have considerably improved. As a result, the side effects and consequences of therapy, their detection, and treatment are becoming an increasingly important part of patient follow-up.